Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 1.00 |
| ▸ | CDK2 | P24941 | 17/20 | 1.00 |
| ▸ | KDR | P35968 | 15/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 1/20 | 1.00 |
| ▸ | CCNH | P51946 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066990 | 1.00 | CDK1 (1.00) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4065828 | 1.00 | CDK1 (1.00) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4065960 | 0.90 | CDK1 (0.82) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL3932334 | 0.90 | CDK1 (0.82) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4058647 | 0.90 | CDK1 (0.82) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4057630 | 0.89 | CDK1 (0.80) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4063258 | 0.89 | CDK1 (0.80) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL13648941 | 0.89 | CDK1 (0.79) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4061119 | 0.89 | CDK1 (0.80) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4072361 | 0.87 | CDK1 (0.77) | CDK1CDK2KDRCA2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | UNM RAINFOREST INNOVATIONS | 2023-06-13 | — | — | US | claimed |
| CN-100480242-C | CDK-inhibiting pyrimidine compounds, method for the production thereof and use thereof as medicaments | SCHERING AG (DE) | 2009-04-22 | — | — | CN | claimed |
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | claimed |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | UNM RAINFOREST INNOVATIONS | 2023-06-13 | — | — | US | disclosed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | SOST, ACP3, KLK3 | CDK1 3269/4885CDK2 2887/4885KDR 664/4885 |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | CDK1 2/4885CDK2 1/4885KDR 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.